CliffBio
small molecule

TROKENDI XR

TOPIRAMATE

Loss of exclusivityApril 2028latest FDA-listed patent expiry
CompanySupernus Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameTROKENDI XR
Active ingredientTOPIRAMATE
Strength50MG
Dosage formCAPSULE, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2013
Marketing statusRX

Listed patents

PatentExpiresType
8298576April 2028product
9549940November 2027product
8877248November 2027product
8889191November 2027use U-1992
10314790November 2027product
8298580November 2027product
8992989November 2027product
9555004November 2027product
9622983November 2027product
8663683November 2027product

More from Supernus Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TROKENDI XR patent cliff — loss of exclusivity April 2028 | CliffBio